Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Me...
April 18 2019 - 7:05AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing treatments that restore and
preserve vision for people with serious eye diseases, announced
today that multiple presentations will be made on Clearside’s
Suprachoroidal Space (SCS®) injection platform at upcoming
ophthalmology and gene therapy medical meetings in Vancouver,
British Columbia. The presentations will highlight the benefits of
the Company’s SCS injection platform when utilized in uveitis
patients and with gene therapy.
Viral Kansara, Ph.D., Clearside Vice
President, Discovery, will give an oral presentation at the 6th
Annual Retinal Cell and Gene Therapy Innovation Summit
Title: |
Suprachoroidally delivered non-viral DNA nanoparticles transfect
chorioretinal cells in non-human primates and rabbits |
Date: |
Friday, April 26, 2019 |
Time: |
5:30 pm – 5:45 pm |
Eric B. Suhler M.D., M.P.H., Oregon
Health and Science University Professor of Ophthalmology and
Co-Director, OHSU Uveitis Clinic, will give an oral presentation at
the American Uveitis Society Spring Meeting 2019
Title: |
Suprachoroidal Administration of Triamcinolone Acetonide (CLS-TA)
For the Treatment of Macular Edema in Noninfectious Uveitis: Pooled
Results of Three Clinical Trials |
Date: |
Saturday, April 27, 2019 |
Event Time: |
5:00 pm – 7:30 pm |
Three poster presentations will be made
at the Association for Research in Vision and Ophthalmology (ARVO)
2019 Conference taking place April 28 – May 2, 2019
Title: |
Suprachoroidal injection of AAV8 for ocular gene delivery in the
nonhuman primate |
Date: |
Tuesday, April 30, 2019 |
Time: |
8:45 am – 10:30 am |
Session: |
Gene Therapy and Delivery |
Poster #: |
A0091 |
Abstract #: |
2904 - A0091 |
|
|
Title: |
Suprachoroidally delivered non-viral DNA
nanoparticles transfect chorioretinal cells in non-human primates
and rabbits |
Date: |
Tuesday, April 30, 2019 |
Time: |
8:45 am – 10:30 am |
Session: |
Gene Therapy and Delivery |
Poster #: |
A0096 |
Abstract #: |
2909 - A0096 |
|
|
Title: |
Treatment response analysis of visual acuity and
central subfield retinal thickness following suprachoroidal
CLS-TA |
Date: |
Tuesday, April 30, 2019 |
Time: |
11:45 am – 1:30 pm |
Session: |
Uveitis and scleritis - clinical therapeutics and
checkpoint inhibitors |
Poster #: |
A0552 |
Abstract #: |
3511 - A0552 |
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing treatments that
restore and preserve vision for people with serious eye diseases.
Clearside’s proprietary suprachoroidal treatment approach offers
unprecedented access to the back of the eye where sight-threatening
disease often occurs. The company’s unique platform for eye disease
treatments is inherently flexible and intended to work with
established medicines, new formulations of medicines, as well as
future innovations such as gene therapy. Clearside is headquartered
in Alpharetta, GA. For more information, please visit
http://www.clearsidebio.com.
Cautionary Note Regarding
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as “believe”, “expect”, “may”, “plan”,
“potential”, “will”, and similar expressions, and are based on
Clearside’s current beliefs and expectations. These forward-looking
statements include expectations regarding the potential benefits of
SCS Injection Platform. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements. Risks and uncertainties
that may cause actual results to differ materially include
uncertainties inherent in the conduct of clinical trials,
Clearside’s reliance on third parties over which it may not always
have full control, and other risks and uncertainties that are
described in Clearside’s Annual Report on Form 10-K for the year
ended December 31, 2018, filed with the U.S. Securities
and Exchange Commission (“SEC”) on March 15, 2019, and
Clearside’s other Periodic Reports filed with the SEC. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Clearside as of
the date of this release, and Clearside assumes no obligation to,
and does not intend to, update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor and Media Contacts: Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Sep 2023 to Sep 2024